FeesSafety
Pluang+

FormFactor raises price target to $170 on strong Q2 earnings and growth outlook

Analyst Insights
15 Sep 2026
Seeking Alpha
View Source
Bullish
FormFactor raises price target to $170 on strong Q2 earnings and growth outlook

FormFactor beat Q2 2026 expectations with $258.2 million in revenue and $0.82 non-GAAP EPS, driven by strong multi-segment performance including HBM, GPU, and custom ASIC testing. The company qualified advanced MEMS technology at a leading foundry, boosting growth prospects. The analyst raised the 2028 non-GAAP EPS estimate from $3.34 to $4.25 and increased the price target from $134 to $170, applying a 40x forward P/E. Key risks include potential slowdowns in AI or HBM spending, execution challenges, and slower adoption of CPO technology.

FormFactor's recent earnings and price target update provide context for technology sector trends. For readers following technology stocks, here is Pluang's market snapshot as of Sep 16, 2026 01:31 WIB: Of 150 priced US tech stocks, 58 rose and 91 fell. Notable movers include GoPro Inc (GPRO) at USD 1.29, down 4.44%, Expensify Inc (EXFY) at USD 2.38, up 4.39%, and Western Digital Corp (WDC) at USD 408.50, down 4.32%.

More News

Canada's Royal Canadian Legion launches 2026 Poppy Campaign with new contactless donations and a commemorative mural.

Canada's Royal Canadian Legion launches 2026 Poppy Campaign with new contactless donations and a commemorative mural.

The Royal Canadian Legion has launched its 2026 National Poppy Campaign introducing a new contactless donation method using smartphones, supported by BMO and Toucan Giving technology. This innovation allows volunteers to collect donations via debit, ...

Others
Bullish
2 hours ago
XBiotech appoints Jan-Paul Simard as Co-CEO alongside Sushma Shivaswamy to strengthen leadership.

XBiotech appoints Jan-Paul Simard as Co-CEO alongside Sushma Shivaswamy to strengthen leadership.

XBiotech Inc. announced the election of Jan-Paul Simard as Co-Chief Executive Officer alongside current CEO Dr. Sushma Shivaswamy, effective October 23, 2026. This leadership change aims to leverage their complementary skills and scientific expertise...

Market News
Bullish
3 hours ago
XBiotech appoints Sushma Shivaswamy and Jan-Paul Simard as co-CEOs to lead antibody therapy development.

XBiotech appoints Sushma Shivaswamy and Jan-Paul Simard as co-CEOs to lead antibody therapy development.

XBiotech Inc. announced the appointment of Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy, with 17 years at the company, has led scientific operations and was interim CEO since December 20...

Market News
Bullish
3 hours ago
McDonald's McRib returns Oct 27, sparking renewed bitcoin price speculation despite mixed past results.

McDonald's McRib returns Oct 27, sparking renewed bitcoin price speculation despite mixed past results.

McDonald's announced the return of its McRib sandwich on October 27, reigniting a quirky market superstition linking the McRib's comeback to bullish bitcoin price movements. Historically, bitcoin posted gains after six McRib returns from 2019 to 2024...

Market News
Neutral
4 hours ago
New York widow prepays $14K funeral to qualify for Medicaid, leftover $5K goes to county, not heirs.

New York widow prepays $14K funeral to qualify for Medicaid, leftover $5K goes to county, not heirs.

A New York widow facing nursing home entry with too much money for Medicaid prepays a $14,000 irrevocable funeral contract to protect her assets. The $9,000 funeral cost is covered, but the remaining $5,000 does not return to her heirs; instead, it g...

Others
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App